Biomarkers in Sarcoidosis Beginning of a New Era?

There is still a highly unmet need for specific and sensitive biomarkers which can be used in management of patients with sarcoidosis. The clinical context dictates the choice of biomarker(s) used to address different clinical questions such as diagnosis, monitoring disease activity, or monitoring response to treatment. Hopefully, prospective studies such as PREDMETH (Effectiveness of Methotrexate Versus Prednisolone as First -line Therapy for Pulmonary Sarcoidosis, and phase III trials on the efficacy of namilumab or efzofitimod will help us to test current biomarkers and discover new potential biomarkers in order to improve clinical management of our patients with sarcoidosis.95,96 Until then, clinicians should be aware of the modest sensitivity and specificity of the current biomarkers used in clinical practice.